Founded in 2004, Omega Fund is a private equity firm based in Boston, Massachusetts. The firm invests in biotechnology and medical device firms in North America and Western Europe.
Omega Funds is an international Life Sciences-focused investment firm focused mainly on late stage investment opportunities across both private and public companies. Omega is also able to provide partial or complete liquidity solutions for venture and growth funds, as well as founders, corporations and other entities.
They are stage agnostic and seek investment in creating, seeding and funding new companies with products, business plans and scientists they believe in. Or they will join other venture capital firms to invest in early, mid and late stage companies seeking to develop technologies and products targeting unmet needs in healthcare and biotechnology. And they will support the capital needs of publicly traded, small-cap life sciences companies with short or medium-term clinical milestones.
Timeline
Funded Companies
A company developing antibody-based biological medicines for kidney diseases and other chronic diseases. Visterra was acquired by Otsuka Pharmaceutical in 2018.
A synthetic biology company that designs, builds and tests genetic circuits for the purposes programming cell therapies. Their first therapeutic candidates are aimed at solid tumors and blood cancer and the company plans to move beyond oncology.
Egalet Corporation is a pharmaceutical company that focuses on abuse resistance opioids
A synthetic biology company using CRISPR to develop a portfolio of genetic medicines.
A clinical-stage biopharmaceutical company in California that focuses developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology.
Formerly BioMedicines, Intarcia Therapeutics is an American biopharmaceutical company developing therapies for diseases with long-term treatment requirements.
Adagio Therapeutics is a Waltham, Massachusetts-based biotechnology company involved in the research and development of therapeutic pharmaceuticals.
Kronos Bio is a Cambridge, Massachusetts-based therapeutics company working on research and development of therapies that modulate historically recalcitrant cancer targets.
A company focused on the discovery and development of treatments for rare inherited diseases.
FoRx Therapeutics is a Basel-based biotechnology company developing a drug discovery platform for cancer drugs.
A drug development company focused on therapeutics for diseases of the nervous system
A company developing pharmaceuticals to treat metabolic disease
A biopharmaceutical company developing small molecule drugs for asthma, chronic allergy and inflammatory conditions
Arrakis is developing RNA-targeted small molecule (rSM) therapies to millions of patients.
JenaValve Technology is an Irvine, California-based company.
Kezar Life Sciences is a South San Francisco, California-based company.
Prevail Therapeutics is a New York City-based company.
Trevi Therapeutics is a New Haven, Connecticut-based company.
Spruce Biosciences is a San Francisco-based company.
Ikena Oncology is a Cambridge, Massachusetts-based company.
Associated investment funds
People
Anne-Mari Paster
Managing Director, Chief Financial Officer
Annie Mitsak
Principal
Claudio Nessi
Managing Director
Dina Chaya
Partner
Francesco Draetta
Principal
Katie Kerfoot
Vice President
Michelle Doig
Partner Head of Corporate Development
Otello Stampacchia
Managing Director
Paulina Hill
Principal
Richard Lim
Managing Director
Thomas Goebel
Principal
Vincent Ossipow
Partner